ELVN
Enliven Therapeutics, Inc.Healthcare$38.83
◆ Neutral
Mkt Cap: $2.32B|Float: 34.1M|SI: 24.1%|DTC: 11.3
Data as of market close Apr 2, 2026
IV Rank
63
IV Pctl
33%
HV 20d
79.9%
52W Range
$13-$41
ATR(14)
$2.67
Exp. Move
±13.9%
P/C Ratio
1.51
Earnings
May 13
GEX Positive
DEX Long
Net Call Premium
IV High
Max Pain Below
Exp. Move Wide
High Put/Call
ELVN Key Options Data
- IV Rank
- 63%
- Total GEX
- $0.00B
- Total DEX
- $0.2M
- Max Pain
- $35.00
- Expected Move
- ±13.9%
- Put/Call OI
- 1.51
- Net Premium
- $0.5M
- Spot Price
- $38.83
Gamma Exposure (GEX)
Delta Exposure (DEX)
Expected Move by Expiration
| Expiration | DTE | Expected Move | Move % | Lower | Upper |
|---|---|---|---|---|---|
| 2026-04-17 | 15 | ±$5.40 | ±13.9% | $33.43 | $44.23 |
| 2026-05-15 | 43 | ±$3.75 | ±9.7% | $35.08 | $42.58 |
| 2026-06-18 | 77 | ±$16.35 | ±42.1% | $22.48 | $55.18 |
| 2026-09-18 | 169 | ±$18.65 | ±48.0% | $20.18 | $57.48 |
| 2026-12-18 | 260 | ±$5.00 | ±12.9% | $33.83 | $43.83 |
| 2027-01-15 | 288 | ±$22.50 | ±57.9% | $16.33 | $61.33 |
Explore ELVN options data including implied volatility rankings, gamma and delta exposure, max pain levels, and expected price moves. AI-generated reports provide directional, income, and earnings analysis.